Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BJ-1301||BJ-1301 is a synthetic analogue of alpha-tocopherol that inhibits NADPH oxidase, which subsequently leads to inhibition of receptor tyrosine kinase signaling, resulting in decreased cell proliferation and reduced tumor growth (PMID: 28536313).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||BJ-1301||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with BJ-1301 resulted in decreased cell proliferation and inhibited phosphorylation of molecules involved in PI3K/Akt and Ras/Erk signaling in non-small cell lung carcinoma (NSCLC) cells in culture, and repressed tumor growth in NSCLC cell line xenograft models (PMID: 28536313).||28536313|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|